41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
Background and purpose Several epidemiologic studies reported increased mortality in patients with GCA, while others found that the overall survival was essentially identical to that of the general ...
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
Background Rheumatoid arthritis (RA) and diabetes mellitus (DM) have common genetic risk factors, while molecular mechanisms behind this commonality have not been studied. Objectives To study ...
Background: Comprehensive, multidisciplinary care is crucial for effective ankylosing spondylitis (AS) management and patient well-being. Despite its recognized importance, the amount of evidence on ...
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...
Correspondence to Professor Annamaria Iagnocco, Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin 10043, Italy; annamaria.iagnocco1{at}gmail.com Objectives Dactylitis is one of ...
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...
Correspondence to Ping-Hsuan Hsieh, Health Economics and Health Technology Assessment, University of Glasgow Institute of Health and Wellbeing, Glasgow G12 8RZ, UK; p.hsieh.1{at}research.gla.ac.uk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback